Q-omics provides the consensus-scored TMEM14C profile across patient tissues and cancer cell-line models. TMEM14C expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM14C is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, TMEM14C RNA expression shows 18,288 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where TMEM14C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM14C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM14C survival associations across molecular data types. TMEM14C RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM14C RNA expression–survival associations across cancer types. High TMEM14C expression shows unfavorable associations in ACC, LIHC, SARC, ESCA and UVM, but favorable associations in LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM14C RNA expression.
This table summarizes TMEM14C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM14C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM14C shows lower tumor expression in KICH and higher tumor expression in LIHC, KIRC, KIRP, HNSC and CHOL. The LIHC box plot shows higher TMEM14C RNA expression in tumor versus normal tissue (log2 FC = +1.315, t-test p < 0.001).
This table shows molecular features associated with TMEM14C in patient tissues and cancer cell lines. In patient samples, TMEM14C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM14C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
